Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 13, Number 2—February 2007


Neutralizing Antibodies after Infection with Dengue 1 Virus

Gustavo Kourí*Comments to Author , Mayling Alvarez*, Rosmari Rodriguez-Roche*, Lídice Bernardo*, Tibaire Montes†, Susana Vazquez*, Luis Morier*, Angel Alvarez*, Ernest A Gould‡, Maria G. Guzman*Comments to Author , and Scott B Halstead§
Author affiliations: *“Pedro Kourí” Tropical Medicine Institute, Havana, Cuba; †Instituto Medicina Tropical, Caracas, Venezuela; ‡Centre for Ecology and Hydrology, Oxford, United Kingdom; §Pediatric Dengue Vaccine Initiative, Bethesda, Maryland, USA;

Main Article

Table 1

Dengue virus strains used in this study

SerotypeStrainPassage no.*Place and year of isolation
DENV-1†Angola4PC6/36 1PVero 1PC6/36Angola, 1988
DENV-2‡A15/814PMB 4PC6/36Cuba, 1981
DENV-2†‡I3486004P C6/36Colombia, 1986
DENV-3116/003P C6/36Cuba, 2000
DENV-4†Dominica7P C6/36Dominica, 1981

**P, passage; C6/36, Aedes albopictus cell line; Vero, green monkey kidney cell line; MB, mouse brain.

†DENV, dengue virus; received from Robert Shope, University of Texas Medical Branch, Galveston, Texas, USA.

‡DENV-2, A15/81 strain (Asian genotype), DENV 2, I348600 (American genotype).

Main Article

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO